ArticleClinical and translational medicine2025

Targeting enabled homolog with daunorubicin inhibits ERK1/2/c-Fos pathway and suppresses hepatocellular carcinoma progression.

Zhi-Mei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.